Follistatin 344 Protocol: Complete Cycling & Dosing Guide

Overview

Follistatin 344 is a research peptide derived from follistatin, an endogenous glycoprotein that acts as a myostatin antagonist. By binding to myostatin (GDF-8) and activin A, it removes the biological "brake" on muscle protein synthesis and satellite cell activation, allowing for enhanced lean mass accumulation and body composition improvements.

The peptide is administered via subcutaneous or intramuscular injection and operates on a specific on/off cycling pattern to maintain receptor sensitivity and minimize systemic exposure. Unlike traditional anabolic steroids, follistatin 344 works through a distinct mechanism that doesn't directly suppress the HPTA (hypothalamic-pituitary-testicular axis) in the same manner, though FSH suppression is a documented secondary effect.

Critical Safety Note: Follistatin 344 is not FDA-approved for human use and remains in the research chemical category. The human safety database is extremely limited. Use constitutes an experimental protocol with poorly characterized long-term risk profiles, including potential tumor promotion, irreversible hormonal disruption, and connective tissue complications from rapid muscle growth outpacing tendon adaptation.

This guide is educational content only and does not constitute medical advice.

Standard Protocol

The industry-standard follistatin 344 protocol follows a simple 10-day on, 10-day off cycling pattern with consistent daily dosing:

Standard Dose: 100 mcg (micrograms) daily via subcutaneous injection Cycle Duration: 10 days on, 10 days off Typical Cycle Length: 2–4 continuous cycles (20–40 days total use within an 8-week window) Injection Sites: Rotate between abdomen, thighs, and deltoids to minimize localized tissue damage Reconstitution: When received as lyophilized powder, reconstitute with 1 mL of bacteriostatic water per 100 mcg vial (creates 100 mcg/mL concentration)

The 10-on/10-off pattern achieves two goals: (1) maintaining receptor sensitivity by preventing downregulation of ActRIIB receptors through periodic washout, and (2) reducing cumulative systemic exposure to an understudied compound.

Many users complete 2–4 consecutive cycles before implementing a longer break (4–8 weeks off). This approach balances anabolic stimulus with practical safety margins given the limited human research.

Goal-Specific Protocols

Lean Mass Accumulation (Primary Goal)

Dose: 100 mcg daily Cycle: 10 days on, 10 days off × 3 cycles (30 days use over 60 days) Nutrition: High protein intake (1.0–1.2 g per pound bodyweight), caloric surplus of 300–500 calories Training: Push/Pull/Legs or Upper/Lower split, 4–5 days per week with progressive overload

This protocol prioritizes muscle growth over fat loss. The extended 3-cycle run allows cumulative satellite cell activation and protein synthesis elevation. Caloric surplus supports the anabolic environment follistatin 344 creates.

Expected gains: 8–15 lbs lean mass over 8 weeks (with proper training and nutrition)

Body Composition Improvement (Lean Mass + Fat Loss)

Dose: 100 mcg daily Cycle: 10 days on, 10 days off × 2 cycles (20 days use over 40 days) Nutrition: Slight caloric deficit (200–300 calories below maintenance), high protein (1.1–1.3 g per pound) Training: 4–5 days resistance training + 2–3 days moderate cardio (LISS or HIIT) Supplements: Thermogenic support (caffeine, yohimbine) optional during off-cycles to maintain fat mobilization

This protocol uses shorter cycling to prevent excessive fat accumulation while follistatin 344 promotes lean mass retention during the deficit. The strategic off-cycle periods allow metabolic adaptation and continued fat loss without peptide stimulus.

Expected changes: 5–10 lbs lean mass, 8–12 lbs fat loss over 8 weeks

Strength & Athletic Performance

Dose: 100 mcg daily Cycle: 10 days on, 10 days off × 2 cycles Nutrition: Adequate protein (1.0 g per pound), maintenance or slight surplus calories Training: Strength-focused, compound-heavy (squats, deadlifts, bench press, rows), 3–4 days per week with focus on progressive strength metrics

Follistatin 344's mechanism supports satellite cell recruitment and myonuclei accretion, directly supporting strength development. This protocol emphasizes intensity and neural adaptation over volume.

Expected gains: Strength increases of 5–15% on major lifts within 4–6 weeks

Advanced / Extended Cycling (Experienced Users Only)

Dose: 100 mcg daily weeks 1–10, then optional drop to 50 mcg daily weeks 11–15 for a "taper" Cycle: 10 days on, 10 days off × 4 cycles, then 6-week washout Rationale: Extended use allows investigation of cumulative effects; taper period may reduce rebound myostatin upregulation

This protocol carries elevated risk and should only be attempted by users with prior peptide experience who understand the unknowns. It is not recommended due to the limited safety data.

How to Administer Step-by-Step

Reconstitution (First-Time Setup)

1. Gather supplies: Lyophilized follistatin 344 vial, bacteriostatic water, 1 mL syringe, 25–27 gauge needle, alcohol prep pads
2. Sanitize the vial: Wipe the rubber stopper with an alcohol pad and allow to air-dry for 30 seconds
3. Draw bacteriostatic water: Fill 1 mL syringe with 1 mL bacteriostatic water
4. Inject into vial: Insert needle and slowly inject water into the vial at an angle to minimize foam formation
5. Gently swirl: Do not shake vigorously; gently rotate the vial for 30–60 seconds until the powder fully dissolves
6. Verify clarity: Solution should be clear or slightly opalescent. If cloudy or particulate matter is visible, discard
7. Draw dose: Use a fresh 1 mL insulin syringe (29–31 gauge) to draw 1 mL (100 mcg)
8. Label the vial: Write the date and concentration on the vial
9. Store: Refrigerate at 2–8°C (36–46°F) for up to 4 weeks; do not freeze

Daily Injection Protocol

1. Timing: Inject once daily, ideally in the morning or evening (consistency matters more than timing)
2. Site selection: Rotate between subcutaneous locations—lower abdomen, outer thighs, deltoids
3. Cleanse site: Wipe injection area with alcohol pad; allow to air-dry completely
4. Pinch skin: For subcutaneous injection, pinch 1–2 inches of skin to create a fold
5. Insert needle: Insert at 45° angle into the subcutaneous fat layer; do not hit muscle (unless performing intramuscular injection deliberately)
6. Inject slowly: Depress plunger over 5–10 seconds to minimize pressure and tissue trauma
7. Withdraw: Remove needle straight out and apply gentle pressure with sterile gauze for 10 seconds
8. Document: Log injection date, site, and any local reactions

Storage & Stability

• Reconstituted vials: Refrigerate at 2–8°C; stable for 4 weeks
• Lyophilized powder: Store at room temperature (15–25°C) in original packaging; stable for 12+ months if kept dry
• Reconstituted solution: Do not freeze; discard if cloudiness, discoloration, or particulates develop
• Needle management: Use fresh needle for each injection; never reuse

Cycle Example: Week-by-Week Schedule

8-Week Lean Mass Protocol

Week 1–2 Expectations: Increased vascularity, slight pump enhancement in training, mild injection site soreness subsides by day 3. Strength may increase noticeably by day 8–10.

Week 3–4 (Off): Natural myostatin rebound occurs; this is normal and expected. Many users report a brief "flat" feeling that resolves by week 4. Lean mass is retained.

Week 5–6: Second cycle produces more pronounced effects; users report enhanced muscle fullness, improved recovery, and strength gains accelerate.

Week 7–8 (Off): Consolidation phase; gains stabilize and become "permanent" relative to baseline.

What to Expect: Timeline of Effects

Days 1–3

• Mild injection site reactions (redness, slight swelling) at injection sites
• Possible low-grade fatigue or mild malaise
• No measurable performance changes yet

Days 4–7

• Injection site reactions typically resolve
• Increased vascularity and muscle fullness, particularly in upper body
• Enhanced "pump" during training
• Slight strength increases may be noticeable
• Some users report improved sleep quality

Days 8–10

• Peak strength increases (5–10% above baseline on major lifts)
• Maximum muscle fullness and vascularity
• Slight body weight gain (mostly lean mass if diet is correct)
• Possible mild joint discomfort if stacking with GH/IGF-1; otherwise minimal

Days 11–15 (Off-Cycle)

• Myostatin levels rebound naturally; this is expected
• Brief "deflation" feeling as intracellular water partially normalizes
• Strength may dip 5–10% but returns to baseline + gains by end of week 2 off
• No dramatic muscle loss; all lean mass gains are largely retained

Days 16–20 (Second Cycle ON)

• Stronger response on second cycle due to priming effect
• Vascularity and pumps return by day 3–4
• Strength increases often exceed the first cycle (common adaptation)

Common Protocol Mistakes

Mistake 1: Injecting Too Frequently

Running daily follistatin 344 for more than 10 consecutive days without a break causes ActRIIB receptor downregulation, reducing efficacy and increasing systemic peptide exposure. The 10-on/10-off pattern exists for this reason.

Correction: Strict adherence to 10-day cycles with complete 10-day breaks.

Mistake 2: Inadequate Nutrition During Cycles

Follistatin 344 creates an anabolic environment, but without sufficient calories and protein, muscle growth is minimal. Users expecting dramatic gains on a deficit or low-protein diet are disappointed.

Correction: Consume 1.0–1.3 g protein per pound bodyweight and 200–500 caloric surplus during on-cycles.

Mistake 3: Poor Injection Technique

Hitting muscle instead of subcutaneous tissue, reusing needles, or injecting into overly sore sites creates localized inflammation, abscesses, and reduced absorption.

Correction: Use 25–27 gauge needles for reconstitution, 29–31 gauge for administration. Rotate sites meticulously. Subcutaneous only unless deliberately performing intramuscular injection.

Mistake 4: Stacking Multiple Myostatin Inhibitors

Combining follistatin 344 with other myostatin-blocking compounds (YK-11, certain SARMs) increases connective tissue strain and unpredictable hormonal effects.

Correction: Use follistatin 344 as a standalone compound or stack only with proven synergistic agents like testosterone and basic amino acid support.

Mistake 5: Neglecting Training Progression

Follistatin 344 only works if the training stimulus is present. Users who coast through training receive minimal gains.

Correction: Implement strict progressive overload; aim for +1–2 reps or +5–10 lbs per week on major compounds.

Mistake 6: Insufficient Washout Before Next Protocol

Running follistatin 344 cycles back-to-back for 12+ weeks without extended breaks increases cumulative dose exposure and raises theoretical risks.

Correction: After 2–4 cycles, implement a 4–8 week complete washout before resuming.

How to Stack with Other Compounds

With Testosterone (Synergistic)

Testosterone amplifies follistatin 344's anabolic effect through complementary mechanisms. Testosterone provides androgenic support while follistatin 344 removes myostatin inhibition.

Protocol:

• Follistatin 344: 100 mcg daily, 10 on/10 off
• Testosterone (any ester): 300–500 mg/week
• Run both simultaneously during follistatin 344 on-cycles
• Risk consideration: Combined FSH suppression; consider HCG if concerned about testicular atrophy

With GH or IGF-1 (Use with Caution)

Growth hormone and IGF-1 amplify follistatin 344's growth-promoting effects but significantly increase connective tissue strain and acromegalic-like joint discomfort. This combination is common among advanced users but carries elevated risk.

Protocol:

• Follistatin 344: 100 mcg daily
• GH: 2–4 IU daily or IGF-1 LR3: 50–100 mcg daily
• Offset administration by 4–6 hours to minimize simultaneous myostatin suppression
• Mandatory: Comprehensive health screening, regular ultrasound monitoring of organs
• Not recommended for users without extensive peptide/hormone experience

With SARMs (Not Recommended)

Combining follistatin 344 with selective androgen receptor modulators (SARMs) like LGD-4033 or RAD-140 creates redundant anabolic signaling without clear benefit. Most experienced users avoid this stack due to overlapping mechanisms and unclear safety data.

If stacking:

• Reduce SARM dose by 25–30%
• Monitor for excessive liver enzyme elevation
• Implement extended washout afterward

With Basic Amino Acids & Creatine (Recommended)

The evidence base directly supports this combination. EAA supplementation (5–10 g daily) and creatine monohydrate (5 g daily) enhance follistatin 344's effects on satellite cell activation and myonuclei accretion.

Protocol:

• Follistatin 344: 100 mcg daily
• EAA: 10 g with breakfast and post-training
• Creatine monohydrate: 5 g daily, split dosing
• Benefit: Lowest-risk combination with direct human evidence

With Thyroid Support (Optional)

Some users add mild thyroid support (T3 or thyroid-stimulating compounds) to enhance fat loss during body composition-focused cycles. This is optional and not necessary.

Protocol:

• Follistatin 344: 100 mcg daily, on/off cycles
• T3: 25–50 mcg daily (if experienced with thyroid drugs)
• Reduce calories by 200 instead of 300 to offset T3-driven metabolism

Protocol Quick Reference Table